type iia topoisomerase inhibition new class antibacterial agents
despite success genomics identifying new essential bacterial genes lack sustainable leads antibacterial drug discovery address increasing multidrug resistance type iia topoisomerases cleave religate dna regulate dna topology major class antibacterial anticancer drug targets yet well developed structural basis understanding drug action report angstrom crystal structure potent new class broad-spectrum antibacterial agent complex staphylococcus aureus dna gyrase dna showing new mode inhibition circumvents fluoroquinolone resistance clinically important drug target inhibitor bridges dna transient non-catalytic pocket two-fold axis gyra dimer interface close active sites fluoroquinolone binding sites inhibitor complex active site seems poised cleave dna single metal ion observed toprim topoisomerase/primase domain scissile phosphate work provides new insights mechanism topoisomerase action platform structure-based drug design new class antibacterial agents clinically proven conformationally flexible enzyme class
